Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SNSS
  • CUSIP: 86732860
  • Web: www.sunesis.com
Capitalization:
  • Market Cap: $55.07 million
  • Outstanding Shares: 21,460,000
Average Prices:
  • 50 Day Moving Avg: $2.83
  • 200 Day Moving Avg: $3.58
  • 52 Week Range: $2.50 - $6.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.21
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $2.57 million
  • Price / Sales: 21.38
  • Book Value: ($0.21) per share
  • Price / Book: -12.19
Profitability:
  • EBIDTA: ($36,020,000.00)
  • Net Margins: -1,472.94%
  • Return on Assets: -109.38%
Debt:
  • Current Ratio: 3.15%
  • Quick Ratio: 3.15%
Misc:
  • Average Volume: 129,130 shs.
  • Beta: 1.77
  • Short Ratio: 1.74
 
Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Monday, May, 8th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.36. The company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $1.57 million. The business's revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. View Sunesis Pharmaceuticals' Earnings History.

When will Sunesis Pharmaceuticals make its next earnings announcement?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Sunesis Pharmaceuticals.

Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued twelve-month price objectives for Sunesis Pharmaceuticals' stock. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.

What are analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (7/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Losing Vosaroxin. SNSS has withdrawn its MAA in the EU for vosaroxin, ending the company’s chances, we believe, for marketing approval without additional clinical studies." (5/2/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:

  • Daniel N. Swisher Jr., President, Chief Executive Officer, Director
  • Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
  • James W. Young Ph.D., Non-Executive Independent Chairman of the Board
  • Stephen B. Ketchum Ph.D., Director
  • Geoffrey M. Parker, Director
  • Steve R Carchedi, Independent Director
  • Matthew K. Fust, Independent Director

Who owns Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BALYASNY ASSET MANAGEMENT LLC (9.32%). Company insiders that own Sunesis Pharmaceuticals stock include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $2.56.


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $3.00 (17.19% upside)

Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/2/2017Cantor FitzgeraldReiterated RatingHold$3.00HighView Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
7/29/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
7/24/2015Roth CapitalDowngradeBuy -> Sell$5.50 -> $1.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2017($0.59)N/AView Earnings Details
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-2.4 EPS
Next Year EPS Consensus Estimate: $-2.11 EPS

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 55.19%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.80View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Source:
DateHeadline
globenewswire.com logoSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:56 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:42 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
finance.yahoo.com - July 18 at 8:48 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) vs. Biohaven Pharmaceutical Holding Co (BHVN) Critical Analysis
www.americanbankingnews.com - July 17 at 9:55 AM
americanbankingnews.com logo-$0.76 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - July 6 at 7:36 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 28 at 7:30 AM
globenewswire.com logoSunesis Pharmaceuticals Added to Russell Microcap® Index - GlobeNewswire (press release)
globenewswire.com - June 27 at 8:01 PM
finance.yahoo.com logoSunesis Pharmaceuticals Added to Russell Microcap® Index
finance.yahoo.com - June 27 at 8:30 AM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) Announces Presentation of ... - StreetInsider.com
www.streetinsider.com - June 24 at 6:51 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
finance.yahoo.com - June 24 at 6:51 AM
americanbankingnews.com logo Analysts Expect Sunesis Pharmaceuticals, Inc. (SNSS) to Post -$0.76 EPS
www.americanbankingnews.com - June 12 at 8:30 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 20 at 5:35 AM
finance.yahoo.com logoThe Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
finance.yahoo.com - May 19 at 10:01 AM
americanbankingnews.com logo-$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - May 15 at 8:16 PM
americanbankingnews.com logoZacks Investment Research Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
www.americanbankingnews.com - May 13 at 11:16 PM
finance.yahoo.com logoEdited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT
finance.yahoo.com - May 13 at 12:44 AM
americanbankingnews.com logoBrokers Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 9:01 PM
finance.yahoo.com logoSunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 10:44 AM
globenewswire.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - May 8 at 3:18 PM
finance.yahoo.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 11:13 AM
finance.yahoo.com logoInvestor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:13 AM
marketbeat.com logoSunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:16 PM
businesswire.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 3 at 11:07 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.
finance.yahoo.com - May 3 at 6:05 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:05 PM
nasdaq.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM
finance.yahoo.com logoSUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
finance.yahoo.com - May 3 at 10:45 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - May 3 at 10:45 AM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.
finance.yahoo.com - May 3 at 10:45 AM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Earns Media Sentiment Score of -0.05
www.americanbankingnews.com - May 2 at 6:12 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS)
finance.yahoo.com - May 2 at 5:46 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS
finance.yahoo.com - May 2 at 5:46 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Angie's List, Tenet, Chegg, AMD, Coach, Merck, Sunesis Pharma - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM
nasdaq.com logoAZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin ... - Yahoo Finance
finance.yahoo.com - May 2 at 9:21 AM
streetinsider.com logoSunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl - StreetInsider.com
www.streetinsider.com - May 2 at 9:21 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 2 at 8:46 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 7:42 PM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
finance.yahoo.com - May 1 at 7:08 PM
finance.yahoo.com logoSunesis shares drop as biotech drops leukemia drug marketing application
finance.yahoo.com - May 1 at 7:08 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Getting Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 29 at 7:59 PM
americanbankingnews.com logoZacks: Analysts Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) to Announce -$0.83 EPS
www.americanbankingnews.com - April 25 at 11:33 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Very Likely to Affect Sunesis Pharmaceuticals (SNSS) Share Price
www.americanbankingnews.com - April 23 at 9:17 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Receiving Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - April 17 at 6:35 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Short Interest Down 4.9% in March
www.americanbankingnews.com - April 16 at 12:20 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Getting Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 9:53 PM

Social

Chart

Sunesis Pharmaceuticals (SNSS) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff